GlaxoSmithKline's development partner, Genmab, stated Thursday that GlaxoSmithKline filed a declaratory judgement action in a US district court over Genentech's Cabilly patent. The Danish drugmaker indicated the action is seeking a declaration that the patent "is invalid, unenforceable and not infringed" by experimental oncology drug Arzerra (ofatumumab).
The Cabilly patent has been disputed previously in separate US litigation. Genentech announced in February that the US Patent and Trademark Office confirmed the patent is valid.
Genmab and GlaxoSmithKline are developing Arzerra under a collaboration agreement signed in 2006.
To read more Top Story articles, click here.